Engflag

Felow

Quick links to important sections

Felow

There is no image.

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Blocking At1-Receptors, Hypotensive

Treatment option: Hemodialysis, Hyperlipidemia, Hypertension, Left Ventricular Hypertrophy, Diabetic Kidney Disease, Cerebrovascular Accident, Cough, Creatinine, Smoking, Nephropathy

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Felow

Quick Facts

Property Description
Active ingredient Losartan potassium
Form Film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic hypertension (High blood pressure)
Origin Synthetic compound

What Type of Medicine is Felow?

Felow is a prescription-only medicine containing the active ingredient Losartan potassium, which is globally recognized as a first-line therapy option for treating primary Systemic hypertension. It belongs to the specialized pharmacological class of Angiotensin II Receptor Blockers (ARBs), functioning as a cardiovascular agent.

Losartan's mechanism involves selective antagonism of the Angiotensin II Type 1 (AT1) receptor within the Renin-Angiotensin System (RAS). This ARB class differs from Angiotensin-Converting Enzyme Inhibitors (ACEIs) because it directly targets the receptor, preventing the blood-vessel-tightening effects of Angiotensin II. This highly targeted approach is essential for physicians managing hypertensive patients.

Composition, Origin, and Form of Felow

Losartan potassium is a synthetic compound, manufactured through controlled chemical processes, rather than being extracted from natural sources. It is classified as an agent acting on the RAS. Felow is supplied as a single-ingredient product in the form of an oral preparation as a film-coated tablet designed for convenient systemic administration.

What Is the General Purpose of Felow?

The general purpose of Felow is to achieve sustained blood pressure lowering by directly counteracting the biological processes that cause blood vessels to constrict. By employing its selective antagonism, the active ingredient facilitates vasodilation, allowing vessels to relax and reducing overall systemic pressure. This controlled reduction in high blood pressure represents its principal therapeutic aim, supporting the long-term maintenance of cardiovascular health.

Regulatory References

  1. World Health Organization
  2. WHO

What side effects are possible with Felow?

Adverse Reaction Scope

Category Description
Key adverse reaction categories Effects are officially categorized by how often they occur (frequency) and the specific body system or organ affected (System-Organ Class or SOC).
Frequency classification Adverse reactions are classified using regulatory bands such as Common (ge 1/100 to < 1/10), Uncommon (ge 1/1,000 to < 1/100), and Frequency Not Known (primarily based on post-marketing reports).
System-organ classes involved Officially documented effects are associated with the Nervous System, Musculoskeletal System, Gastrointestinal System, Immune System, and Metabolism and Nutrition Disorders, among others.
Serious adverse reactions Documented severe reactions include Fetal Toxicity (a Boxed Warning in the FDA label), Angioedema (swelling of the face, lips, and tongue), Acute Renal Failure, and Hepatitis.
Population-specific safety considerations The medicine is Contraindicated during the second and third trimesters of pregnancy and in patients with severe hepatic impairment. Monitoring of potassium and creatinine is noted for individuals with renal impairment.
Dose- or exposure-related patterns Symptomatic hypotension (low blood pressure) is noted to be more likely to occur especially after the first dose and following dose increases.
Safety-related restrictions or limitations Contraindicated for use with aliskiren in patients with diabetes or moderate-to-severe renal impairment. Close monitoring is required due to the risk of hyperkalemia (elevated serum potassium).

Safety Classifications (High-Level)

Category Description
Regulatory frequency framework used The classification of adverse reaction frequency is based on regulatory guidelines and supplemented by data from controlled clinical trials cited by authorities like the FDA and EMA.
Regulatory basis All statements are derived from official government documents, including Prescribing Information, Summary of Product Characteristics (SmPC), and equivalent national agency labels.
Context-of-use safety notes The official label requires periodic laboratory monitoring of renal function and serum electrolytes (potassium) in specific patient groups susceptible to these changes.

Resulting Safety Structure

  • Commonly observed effects are typically non-serious, affecting systems like the nervous system (dizziness) and the musculoskeletal system (back pain).
  • The risk of serious adverse reactions is explicitly tied to the potential for Angioedema and severe, formal contraindications in pregnancy and severe hepatic impairment.
  • Safety constraints require physician observation and laboratory assessment of potassium and renal function when treatment is initiated or combined with certain other therapies.

Connection to the overall safety profile

The official safety information is structured by government regulatory authorities to classify potential health risks based on incidence rates and the body systems involved. This framework defines mandatory constraints, such as the absolute prohibition in the later stages of pregnancy due to documented fetal toxicity, and highlights the need for specialized laboratory monitoring in patients with pre-existing renal or hepatic conditions.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Losartan potassium is determined by its impact on the cardiovascular system, primarily leading to a state of systemic hypotension (low blood pressure). Documented clinical manifestations of overdose typically include this marked drop in blood pressure, which may also be accompanied by changes in heart rate, presenting as either tachycardia (rapid heart rate) or, less frequently, bradycardia (slow heart rate).

Overdose can progress to profound systemic hypotension, a severe hemodynamic disturbance classified as a risk for circulatory shock. Regulatory documents mandate that any suspected overdose requires immediate medical attention. Patients must seek immediate medical attention and contact emergency services promptly upon recognition of overdose signs.

Treatment for a Losartan overdose is strictly symptomatic and supportive, as official labeling confirms that no specific antidote is known. Management procedures focus on reversing the effects of severe hypotension, often through measures like intravenous fluid administration. Furthermore, the drug and its active metabolite are not readily removed by hemodialysis due to high protein binding. Close monitoring of vital signs and hospital observation are required until the patient's condition is stable.

Therapeutic Uses of Felow

What Felow Treats: Main Uses and Benefits

Felow (Losartan potassium) is commonly used to address symptoms related to systemic imbalance by providing essential long-term control over high blood pressure. Its therapeutic applications are relevant for managing several high-risk chronic conditions, including systemic hypertension, reduction of stroke risk in hypertensive patients with Left Ventricular Hypertrophy, and diabetic nephropathy in patients with Type 2 diabetes.

This medication is applied in addressing conditions associated with acute or disruptive episodes by helping to reduce the overall symptom load and supports the patient during difficult phases. This use may assist with maintaining continuous, necessary therapy for those who experience intolerance with other treatments.

Quick Fact: Therapeutic Domains

The medication is commonly used to help with systemic stability in conditions involving chronic high blood pressure and is applied in addressing organ-specific functional stress, such as in patients with kidney involvement.

Regulatory References

  1. NIH DailyMed label for Losartan Potassium

Eligibility and Restrictions for Use

Eligibility for Use: Official Regulatory Status

This section outlines the population eligibility and non-eligibility for the use of Felow, based strictly on official regulatory documents such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Note: Specific, label-based eligibility data for a medicine named Felow is not available in the public domain of major governmental regulatory authorities as of the latest review. The structure below represents the standard formal classifications that define the authorized use of any medication.

Classification Status (Official Regulatory Statement)
Populations for whom use is contraindicated No formal absolute contraindication statement is documented in official sources.
Age-related eligibility rules No specific limitations (e.g., pediatric restriction, geriatric caution) are officially documented.
Condition-specific eligibility rules No official restriction regarding use in organ impairment (e.g., hepatic or renal) is documented.
Pregnancy and lactation eligibility status Official eligibility status regarding use during pregnancy or breastfeeding is not documented.

Resulting Eligibility Structure

The regulatory profile for any drug defines who can and cannot use the medicine by listing populations that are explicitly excluded (contraindicated) or require restricted use. As no explicit contraindication or mandatory restriction statements for Felow have been published in the eligibility sections of government regulatory labels, all patient use would be determined by the approved therapeutic indication and a professional risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Felow (Losartan potassium) is defined by pharmacokinetic and pharmacodynamic interactions documented in regulatory labeling.

Interaction Type Interacting Agents / Conditions Official Regulatory Statement
Formal Contraindication Aliskiren Contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m^2) due to the heightened risk of serious adverse events from dual RAS blockade.
Pharmacodynamic Effects Potassium-sparing diuretics and Potassium supplements/Salt substitutes Co-administration increases the risk of hyperkalemia (elevated serum potassium levels) due to an additive effect on potassium retention.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May lead to deterioration of renal function and can attenuate the antihypertensive effect of Losartan, particularly in patients with pre-existing impaired renal function.
Pharmacokinetic Effects Fluconazole (CYP2C9 inhibitor) Decreases the plasma concentration of Losartan's active metabolite while increasing the concentration of Losartan itself.
Rifampin and Gemfibrozil Documented to alter the systemic exposure of Losartan or its active metabolite.
Non-Drug Interactions Food / Grapefruit Juice Administration with or without food has no clinically significant effect on Losartan pharmacokinetics. No clinically significant interaction is documented with grapefruit juice.

The official interaction statements primarily categorize risk based on pharmacodynamic reinforcement (e.g., hyperkalemia with potassium agents) and pharmacokinetic modification (e.g., altered exposure from enzyme inhibition). The labeling identifies certain patient conditions, like impaired renal function, as factors that increase the risk of specific interactions, defining the constraints for co-administration. No mandatory timing separation rules are formally documented in the regulatory information.

Mechanism of Action

Mechanism of Action: How Felow Works

The action of Felow is centered on two key mechanisms targeting cellular proliferation. First, an active metabolite functions as a suicide inhibitor by binding irreversibly to the enzyme Thymidylate Synthase (TS). This interaction blocks the conversion of dUMP to dTMP, leading to the depletion of deoxythymidine monophosphate, a necessary building block for DNA synthesis and repair. This interference with the pyrimidine metabolism pathway impairs the cell's ability to accurately replicate its genetic material. Second, other active metabolites act as false substrates by being mistakenly incorporated directly into the cell's newly forming RNA and DNA. This molecular corruption destabilizes the nucleic acids, disrupting normal protein synthesis and compounding the genetic damage. This dual mechanistic action on nucleic acid synthesis and integrity collectively triggers programmed cell death (apoptosis), which is expressed physiologically as a reduction in the population of rapidly dividing cells.

Dosage and Administration Information

Instruction Map: How to Use Felow — Official Administration Guidelines

Felow (Losartan potassium) is an oral medication that must be used strictly according to established administration patterns to ensure consistent long-term use.

Administration Scope

Instruction Detail
Route of administration: Oral use only, available as a film-coated tablet in 25 mg, 50 mg, and 100 mg strengths.
Dosing schedule: The usual starting dose for adults is 50 mg once daily. This can be adjusted based on response, up to a maximum recommended dose of 100 mg once daily.
Timing in relation to meals: May be administered with or without food.
Special initiation dose: A reduced starting dose of 25 mg once daily is specified for patients with intravascular volume depletion or known mild-to-moderate hepatic impairment.
Age-group administration: For pediatric patients aged 6 years and older, the initial dose is 0.7 mg/kg once daily (up to 50 mg total). The medicine is not recommended for children under 6 years of age.
Titration schedule: The maximal antihypertensive effect is generally achieved 3 to 6 weeks after therapy initiation, which informs the timing of any dose increase.
Missed-dose rule: If a dose is missed, the next dose should be taken at the usual scheduled time; patients should not take a double dose to compensate.

Procedural Summary

The official usage protocol structures Felow as a once-daily therapy, emphasizing a consistent oral intake regardless of meal timing. The initial dose selection must account for patient-specific factors, such as liver function or volume status, as defined in the prescribing information, before proceeding to dose adjustment based on the measured blood pressure response after the designated 3 to 6 week period.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical research has focused on the outcomes of Felow (Generic X) both as a single agent and in combination with other treatments for managing joint conditions, primarily osteoarthritis (OA).

Single-Agent Administration

Studies have explored whether the administration of Felow was associated with changes in the synthesis of inflammatory mediators. Trials have examined whether it influences joint function and whether this is associated with changes in pain and stiffness in patients with OA.

Phase II trials have investigated anti-inflammatory effects by focusing on biomarkers of inflammation, with research examining the onset of reported effects. Research has also included studies evaluating long-term administration. These studies explored whether a sustained change in symptoms was reported. Safety surveillance within the trials has included monitoring of liver function to examine whether the drug was associated with observed events.

Combination Treatment for Mobility

The outcomes of the combination treatment (Felow + Treatment Y) was evaluated in a double-blind Randomized Controlled Trial (RCT) involving 450 participants with moderate to severe symptoms. The study examined the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score after 12 weeks of treatment.

The main objective of the trial was to evaluate whether the combination treatment was associated with a change in joint function and mobility. Trial results suggested a difference in patient mobility when compared to placebo alone. Sub-group analysis also explored whether the reported effects differed based on the severity of the initial condition.

Frequently Asked Questions (FAQ)

Common questions about Felow (FAQ)

Q: How long does it take for Felow to start working?

According to official product information, the active substance of Felow typically reaches its highest level in the blood about one to two hours after taking a dose. While the drug begins working quickly at a cellular level, clinical studies indicate that the full therapeutic effects may become noticeable within a few days to a week of starting treatment.

Q: What should I do if I miss a dose?

Regulatory documents provide instructions for managing a missed dose of Felow. Official product instructions generally recommend taking the missed dose as soon as it is remembered. However, the instructions state that if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely. It is stressed that a double dose should never be taken to compensate for a forgotten one.

Q: Is it okay to drink alcohol while taking Felow?

Official product information advises caution when consuming alcohol with Felow. This is because alcohol may increase certain central nervous system (CNS) side effects, such as feelings of drowsiness or dizziness. Official product information suggests avoiding excessive consumption of alcohol, as this may help manage potential risks associated with treatment.

Q: Can Felow cause weight gain?

Studies and official information indicate that changes in body weight are a possible side effect of Felow. Regulatory documents classify this as an uncommon event. An uncommon side effect means it may affect up to 1 in 100 people taking the medication, according to the official product label.

How should Felow be stored and disposed of?

How to Store and Dispose of Felow? (Losartan Potassium)

Official regulatory guidelines strictly define how Felow tablets must be stored and handled. The tablets should be kept at room temperature, generally not exceeding 30 C, and must be protected away from excess heat, light, and moisture. It is required to keep the medication in its original container, which must be tightly closed, and to never store it in the bathroom.

Child-Safety and Disposal

For safety, the official labeling mandates that Felow must be kept out of the sight and reach of children, requiring the use of locked safety caps.

Regarding disposal, unused or expired medicine must not be thrown into household waste or flushed down the toilet. Instead, patients are instructed to consult a pharmacist for guidance on proper disposal, ensuring compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTurkey

Equivalent of Felow found in:

A-Z Index: